OIP	E JC18			/	1625
ALEM STEP	S O LAND	: Tan, Z. et al : 10/074,895 : February 12, 2002 : Process for Synthesis of Heteras Antiinflammatory Agents	Docket No.:) Art Unit:) Examiner:	9/200US 1625	127/n
	Commissioner f Washington, D.			AUG 0 6 2002 TECH CENTER 1600/	
	July 24, 2002	SUPPLEMENTAL TRANSI INFORMATION DISCLO			OCPY OF PAPERS ORIGINALLY FILED
	Sir: Transmitted her Statement under	rewith concerning the subject app r 37 C.F.R. §§1.56 and	lication is an Info	ormation Disclosure	
	national applica in 37 C.F.R. §1.	This Statement is being file tion; within three months of the d 491 in an international application herits, whichever event occurs last	late of entry of the n; or before the n	ne national stage as set fo	of a orth
	1.97(c). C.F.R. §1.97(b) of allowance unaccompanied by	, but before the mailing date of einder 37 C.F.R. §1.311, whichever	ther a final actio	n under §1.113 or a notic	ce
: .		A certification as specified in 37 (C.F.R. §1.97(e);	or	
,		The fee set forth in 37 C.F.R. §1.1	7(p).		
	[The Assistant Commission of the \$240.00 fee set forth in 37 (nt

02-2955.

٠.,٠

1.97(d). This Statement is being filed after the mailing of either a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first, but before payment of the issue fee. This Statement is being accompanied by a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of this
Statement, and the petition fee set fort in 37 C.F.R. §1.17(i).
The Assistant Commissioner is hereby authorized to charge payment of the \$130.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.
Triplicate copies of this form are enclosed.
Respectfully submitted,
Mety P. Botte
Anthony P. Bottino Attorney for Applicant(s)

Reg. No. 41,629

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope Addressed to:

Commissioner for Patents Washington, D.C. 20231

On July 24, 2002

By Anthony P. Bottino
Reg. No. 41,629

Patent Department

Boehringer Ingelheim Corp. 900 Ridgebury Road

P.O. Box 368

Ridgefield, CT. 06877 Tel.: (203) 791-6764

6	- 40	17.
n.	3 0 200	1
ALEX	THAT	HEE.

OPPY OF PAPERS ORIGINALLY FILED

RECEIVED Complete If Known Application Number 10/074,895 Substitute for form 1449B/PTO February 12, 2002 Filing Date First Named Inventor Tan, Z. et al **NON-PATENT DOCUMENTS** TECH CENTER 600/2900 Group Art Unit 1625 SUBMITTED BY APPLICANT **Examiner Name** Attorney Docket Number 9/.200US Sheet 1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Initials No. International Search Report - 05/07/2002 AO1 AO₂ AO₃ A04 A05 **AO6** A07 Ш AO8 **A09 AO10** AO11

Examiner Signature Date Cons	sidered 6 1241	4
------------------------------	----------------	---

IN	THE UNITED STATES PA	ATENT AND TRADE	MARK OFFICE
	f: Tan, Z. et al : To be assigned : February 12, 2002 : Process for Synthesis of as Antiinflammatory Ag) Examiner: f Heteroaryl-substituted	To be assigned
Commissione Washington, I			
February 12, 2	2002		
TRANSM	ITTAL LETTER FOR IN	FORMATION DISCL	OSURE STATEMENT
Sir:	·		
	erewith concerning the subjected are subjected are subjected and left are subjected are subjected are subjected as a subjected are subjected are subjected as a s	ect application is an Info	rmation Disclosure
national applicin 37 C.F.R. §	This Statement is be cation; within three months of 1.491 in an international apprendict, whichever event occ	of the date of entry of the olication; or before the n	e national stage as set forth
C.F.R. §1.97(). This Statement is be be), but before the mailing dam under 37 C.F.R. §1.311, which by:	te of either a final action	under §1.113 or a notice
	A certification as specified	in 37 C.F.R. §1.97(e); o	r
	The fee set forth in 37 C.F.	R. §1.17(p).	
-	The Assistant Comrof the \$240.00 fee set forth 02-2955.	•	orized to charge payment Deposit Account No.

1.97(d). This Statement is being filed after the mailing of either a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first, but before payment of the issue fee. This Statement is being accompanied by a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of this Statement, and the petition fee set fort in 37 C.F.R. §1.17(i).
The Assistant Commissioner is hereby authorized to charge payment of the \$130.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.
Triplicate copies of this form are enclosed.

Patent Department

P.O. Box 368

900 Ridgebury Road

Ridgefield, CT. 06877

Tel.: (203) 791-6764

Boehringer Ingelheim Corp.

Respectfully submitted,

Anthony P. Bottino

Attorney for Applicant(s)

Reg. No. 41,629

EXPRESS MAIL LABEL NO. EL904730340US Deposited: February 12, 2002

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

BY: ANTHONY P. BOTTINO

Reg. No. 41,629

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

control number. Compl t if Known Substitute for form 1449A/PTO **Application Number** To be assigned INFORMATION DISCLOSURE February 12, 2002 Filing Date STATEMENT BY APPLICANT First Named Inventor Tan, Z. et af To be assigned Art Unit (use as many sheets as necessary) To be assigned **Examiner Name** Attorney Docket Number 9/200US of Sheet

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials		Document Number Number - Kind Code ² (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AMIC		us- 6.319,921B1	11/20/2001	Cirillo, P.F. et al	
311		us- 6,080,763	06/27/2000	Regan, J.R. et al	
		US-			
	·_ ·	US-			
		us.			
		us-			

	FOREIGN PATENT DOCUMENTS									
	No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76				
1040		WO 00/55139 A2	09/21/2000	Boehringer Ingelheim						
700		WO 00/55139 A3	09/21/2000	Boerhinger Ingelheim						
		WO 01/32627	10/27/2000	Boehringer Ingelheim						
		WO 01/90072	05/15/2001	Boehringer Ingelheim						
BULL		WO 01/04115	06/27/2000	Boehringer Ingelheim						

Examiner	1/ //	Date		27/6)(/
Signature		Considered	0/0	<u> </u>	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	or form 1449B/PTO			Compl t if Known			
			0.00	Application Number	To be assigned		
INFOR	KIMAHON E	JIS	CLOSURE	Filing Date	February 12, 2002		
STATI	EMENT RY	′ Δ	PPLICANT	First Named Inventor	Tan, Z. et al		
O I A I I		_	LIOAN	Group Art Unit	To be assigned		
	(use as many shee	ets a	s necessary)	Examiner Name	To be assigned		
Sheet	2	of	2	Attorney Docket Number	9/200US		

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	7			
TUK		New Aryl/Heteroaryl C-N Bond Cross-coupling Reactions via Arylboronic Acid/Cupric Acetate Arylation PATRICK Y.S. LAM, et al; Tetrahedron Letters 39,(1998) 2941-2944				
BUIL		Application No.09/902,085 filed 07/11/2001, KAPADIA, S. et al; A NOVEL SYNTHESIS FOR HETEROARYLAMINE COMPOUNDS				
· · · · · · · · · · · · · · · · · · ·						

Examiner	~ /i	Date	6/23/134
Signature		Considered	92/01

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.